DIABETES OBESITY & METABOLISM
DIABETES OBESITY & METABOLISM(英文缩写 DIABETES OBES METAB),ISSN 1462-8902,eISSN 1463-1326 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-21 至 2026-09-21，按本站收录文献的发表日期统计。
指标来源：jcr_cas_ifqb
期刊简介
暂无简介。
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 6.408 | Q1 |
| 2022 | 5.800 | Q1 |
| 2023 | 5.400 | Q1 |
| 2024 | 5.700 | Q1 |
| 2025 | 6.100 | Q1 |
DIABETES OBESITY & METABOLISM 最新收录文献
-
1. Long-Term Follow-Up Incidence of Type 1 Diabetes and Associated Autoimmune Diseases in First-Degree Relatives.
PMID:作者:日期:2026-10-01First-degree relatives (FDRs) of individuals with type 1 diabetes (T1D) carry a significantly elevated risk of developing autoimmune diseases, including celiac disease (CD) and autoimmune thyroid disease (AITD). The DiaUnion 1.0 study aimed to characterize one-time autoantibodies, genetic risk profi…
-
2. Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs.
PMID:作者:日期:2026-10-01To examine the effect of second-line treatments (insulin secretagogues, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose co-transporter 2 (SGLT-2) inhibitors) on time to insulin initiation among patients with type 2 di…
-
3. Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.
PMID:作者:日期:2026-10-01Tirzepatide has demonstrated substantial weight-loss efficacy in clinical trials, but real-world evidence from routine digital prescribing remains limited. We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 a…
-
4. Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real-World National Study.
PMID:作者:日期:2026-10-01Evidence regarding the efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real-world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes. This multicenter retrospective study included adults w…
-
5. Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.
PMID:作者:日期:2026-10-01This post hoc analysis of COMBINE 1-3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once-weekly combination therapy of basal insulin icodec and semaglutide [a glucagon-like peptide-1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroup…
-
6. The 'Slow Burn' Phenotype: How Relative Caloric Intake Reveals Hidden Cardiovascular Risk Beyond BMI.
PMID:作者:日期:2026-10-01Body mass index (BMI) inadequately captures heterogeneity in cardiovascular (CV) risk. We hypothesised that a 'Slow Burn' phenotype, defined as lower-than-expected energy intake relative to BMI, age, and sex, identifies individuals at elevated CV risk across the BMI spectrum. We analysed 160 905 Whi…
-
7. SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population-Based Cross-Sectional Study of Uptake of NICE Guidance.
PMID:作者:日期:2026-10-01An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months aft…
-
8. GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.
PMID:作者:日期:2026-10-01Japan's optimal use guideline restricts insurance-reimbursed GLP-1 receptor agonist (GLP-1 RA) therapy for obesity to patients completing a mandatory 6-month lifestyle intervention, caps treatment at 68 weeks (semaglutide 2.4 mg) or 72 weeks (tirzepatide), and mandates subsequent washout. We evaluat…
-
9. Factors Associated With Progression From Level 1 to Level 2 Sensor-Detected Hypoglycaemia in People With Type 1 and Insulin-Treated Type 2 Diabetes: A Post Hoc Analysis From the Hypo-METRICS Study.
PMID:作者:日期:2026-10-01We investigated the proportion of sensor-detected hypoglycaemic (SDH) events progressing to level 2, and associated variables. We used data from Hypo-METRICS, which recruited people with type 1 (pwT1D) and insulin-treated type 2 diabetes (pwT2D) with ≥ 1 hypoglycaemic event in preceding 3 months, we…
-
10. Absence of Interaction Between 5α-Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes.
PMID:作者:日期:2026-10-01People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α-reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co-prescription of both drugs. …